Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Over the last 12 months, insiders at Ardelyx, Inc. have bought $0 and sold $11.54M worth of Ardelyx, Inc. stock.
On average, over the past 5 years, insiders at Ardelyx, Inc. have bought $1M and sold $4.87M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 567,000 shares for transaction amount of $1M was made by MOTT DAVID M (director) on 2022‑11‑17.
2024-06-21 | Sale | Blanks Robert | See Remarks | 38,000 0.0146% | $5.96 | $226,290 | -0.41% | |
2024-06-13 | Sale | RAAB MICHAEL | President & CEO | 35,000 0.015% | $6.65 | $232,743 | -5.08% | |
2024-06-05 | Sale | Williams Laura A | Chief Medical Officer | 145,000 0.0619% | $7.12 | $1.03M | -10.94% | |
2024-06-03 | Sale | Rosenbaum David P. | Chief Development Officer | 17,872 0.0077% | $7.00 | $125,104 | -6.79% | |
2024-05-29 | Sale | RAAB MICHAEL | President & CEO | 7,500 0.0033% | $6.72 | $50,390 | -2.04% | |
2024-05-21 | Sale | RAAB MICHAEL | President & CEO | 31,484 0.0136% | $7.81 | $245,922 | -14.34% | |
2024-05-21 | Sale | Rodriguez Susan | Chief Commercial Officer | 6,703 0.0029% | $7.81 | $52,357 | -14.34% | |
2024-05-21 | Sale | Williams Laura A | Chief Medical Officer | 4,794 0.0021% | $7.81 | $37,446 | -14.34% | |
2024-05-21 | Sale | Blanks Robert | See Remarks | 4,855 0.0021% | $7.81 | $37,922 | -14.34% | |
2024-05-21 | Sale | Renz Justin A | Chief Financial Officer | 5,167 0.0022% | $7.81 | $40,359 | -14.34% | |
2024-05-21 | Sale | GRAMMER ELIZABETH A | See Remarks | 6,927 0.003% | $7.81 | $54,107 | -14.34% | |
2024-05-21 | Sale | Rosenbaum David P. | Chief Development Officer | 7,053 0.003% | $7.81 | $55,091 | -14.34% | |
2024-05-21 | Sale | Felsch Robert Ora | See Remarks | 3,485 0.0015% | $7.81 | $27,221 | -14.34% | |
2024-05-14 | Sale | RAAB MICHAEL | President & CEO | 3,000 0.0013% | $7.99 | $23,970 | -13.41% | |
2024-05-06 | Sale | GRAMMER ELIZABETH A | See Remarks | 284,170 0.1178% | $8.88 | $2.52M | -25.05% | |
2024-05-06 | Sale | Felsch Robert Ora | See Remarks | 207,988 0.0855% | $8.81 | $1.83M | -25.05% | |
2024-05-03 | Sale | Williams Laura A | Chief Medical Officer | 39,949 0.0164% | $8.35 | $333,574 | -21.03% | |
2024-05-03 | Sale | GRAMMER ELIZABETH A | See Remarks | 45,000 0.02% | $9.00 | $405,000 | -21.03% | |
2024-04-29 | Sale | RAAB MICHAEL | President & CEO | 30,000 0.0128% | $6.40 | $192,057 | +6.19% | |
2024-04-15 | Sale | RAAB MICHAEL | President & CEO | 7,500 0.0033% | $7.06 | $52,924 | -1.32% |
RAAB MICHAEL | President & CEO | 1270273 0.3739% | $6.11 | 1 | 38 | +247.57% |
Rosenbaum David P. | Chief Development Officer | 158502 0.1654% | $6.11 | 1 | 46 | +247.57% |
Rodriguez Susan | Chief Commercial Officer | 449092 0.1495% | $6.11 | 0 | 16 | |
GRAMMER ELIZABETH A | See Remarks | 199469 0.1188% | $6.11 | 2 | 38 | +116.79% |
Williams Laura A | Chief Medical Officer | 322152 0.1147% | $6.11 | 1 | 12 | +247.57% |
Blanks Robert | See Remarks | 324331 0.1122% | $6.11 | 0 | 23 | |
Renz Justin A | Chief Financial Officer | 300546 0.0786% | $6.11 | 1 | 17 | +247.57% |
Felsch Robert Ora | See Remarks | 95127 0.0504% | $6.11 | 1 | 7 | +247.57% |
BARRIS PETER J | 10 percent owner | 8752543 3.7704% | $6.11 | 3 | 1 | +14.35% |
BARRETT M JAMES | 10 percent owner | 8752543 3.7704% | $6.11 | 3 | 1 | +14.35% |
KERINS PATRICK J | 10 percent owner | 8752543 3.7704% | $6.11 | 3 | 0 | +14.35% |
KOLLURI KRISHNA KITTU | 10 percent owner | 8752543 3.7704% | $6.11 | 3 | 1 | +14.35% |
New Enterprise Associates 12, Limited Partnership | 10 percent owner | 8752543 3.7704% | $6.11 | 4 | 0 | +10.76% |
DRANT RYAN D | 10 percent owner | 7488893 3.2261% | $6.11 | 1 | 0 | +13.2% |
Sakoda Jon | 10 percent owner | 2665520 1.1482% | $6.11 | 2 | 0 | +14.92% |
MAKOWER JOSHUA | 10 percent owner | 2665520 1.1482% | $6.11 | 2 | 0 | +14.92% |
NEA 15 GP, LLC | 10 percent owner | 2665520 1.1482% | $6.11 | 2 | 0 | +14.92% |
Weller Harry R | 10 percent owner | 2665520 1.1482% | $6.11 | 2 | 0 | +14.92% |
Sonsini Peter W. | 10 percent owner | 2665520 1.1482% | $6.11 | 2 | 0 | +14.92% |
Viswanathan Ravi | 10 percent owner | 2665520 1.1482% | $6.11 | 2 | 0 | +14.92% |
Florence Anthony A. Jr. | 10 percent owner | 2665520 1.1482% | $6.11 | 2 | 0 | +14.92% |
BASKETT FOREST | 10 percent owner | 2258850 0.9731% | $6.11 | 3 | 8 | +14.35% |
SANDELL SCOTT D | 10 percent owner | 2258850 0.9731% | $6.11 | 3 | 8 | +14.35% |
MOTT DAVID M | director | 1166765 0.5026% | $6.11 | 8 | 0 | +20.54% |
SCHULTZ PETER G | director | 907429 0.3909% | $6.11 | 1 | 0 | +13.2% |
Seeto Reginald | Chief Operating Officer | 149885 0.0646% | $6.11 | 0 | 1 | |
Kaufmann Mark | Chief Financial Officer | 141418 0.0609% | $6.11 | 0 | 8 | |
Jacobs Jeffrey W | Chief Scientific Officer | 119483 0.0515% | $6.11 | 0 | 21 | |
CMEA Ventures VII LP | 10 percent owner | 80990 0.0349% | $6.11 | 1 | 2 | 0% |
Korner Paul | EVP, Chief Medical Officer | 54623 0.0235% | $6.11 | 0 | 1 | |
RINGOLD GORDON | director | 25000 0.0108% | $6.11 | 3 | 0 | +13.85% |
JUE GEORGE | VP, Operations | 24134 0.0104% | $6.11 | 0 | 1 | |
Caldwell Jeremy S | EVP, Chief Scientific Officer | 17985 0.0077% | $6.11 | 0 | 3 | |
Bertrand William C JR | director | 5000 0.0022% | $6.11 | 1 | 0 | <0.0001% |
Janus Henderson | $160.86M | 9.42 | 22.05M | -10.59% | -$19.05M | 0.09 | |
BlackRock | $124.8M | 7.31 | 17.1M | +1.91% | +$2.34M | <0.01 | |
State Street | $102.85M | 6.02 | 14.09M | -17.62% | -$22M | <0.01 | |
The Vanguard Group | $97.76M | 5.72 | 13.39M | +2.81% | +$2.67M | <0.01 | |
Eventide Asset Management | $49.73M | 2.91 | 6.81M | +0.11% | +$54,560.20 | 0.78 | |
Geode Capital Management | $38.03M | 2.23 | 5.21M | +4.27% | +$1.56M | <0.01 | |
T. Rowe Price | $28.57M | 1.67 | 3.91M | +68.03% | +$11.57M | <0.01 | |
Macquarie Group | $26.91M | 1.58 | 3.69M | New | +$26.91M | 0.02 | |
Voloridge Investment Management, LLC | $24.1M | 1.41 | 3.3M | +190.31% | +$15.8M | 0.05 | |
Nuveen | $23.32M | 1.37 | 3.19M | +51.54% | +$7.93M | 0.01 | |
Two Sigma | $18.7M | 1.1 | 2.56M | +445.9% | +$15.28M | 0.03 | |
Morgan Stanley | $17.58M | 1.03 | 2.41M | -24.85% | -$5.81M | <0.01 | |
Redmile Group | $16.02M | 0.94 | 2.19M | New | +$16.02M | 0.59 | |
Northern Trust | $15.69M | 0.92 | 2.15M | -1.78% | -$284,028.40 | <0.01 | |
Oracle Investment Management Inc | $14.89M | 0.87 | 2.04M | +135.88% | +$8.58M | 2.01 | |
Goldman Sachs | $14.54M | 0.85 | 1.99M | +80.38% | +$6.48M | <0.01 | |
Charles Schwab | $13.53M | 0.79 | 1.85M | +2.04% | +$270,793.50 | <0.01 | |
Helm Capital Management LLC | $13.26M | 0.78 | 1.82M | -54.73% | -$16.03M | 0.39 | |
Susquehanna International Group | $11.95M | 0.7 | 1.64M | -36.79% | -$6.95M | 0.01 | |
Cubist Systematic Strategies | $10.27M | 0.6 | 1.41M | +953.84% | +$9.3M | 0.09 | |
Deutsche Bank | $9.74M | 0.57 | 1.33M | +17.81% | +$1.47M | <0.01 | |
Millennium Management LLC | $9.63M | 0.56 | 1.32M | New | +$9.63M | 0.01 | |
Jane Street Capital | $8.91M | 0.52 | 1.22M | +11.39% | +$911,441.47 | 0.01 | |
Rafferty Asset Management Llc | $7.7M | 0.45 | 1.06M | -23.28% | -$2.34M | 0.02 | |
Lion Point Capital LP | $7.64M | 0.45 | 1.05M | -9.12% | -$766,499.99 | 14.81 | |
Bank of America | $7.61M | 0.45 | 1.04M | +126.74% | +$4.26M | <0.01 | |
BNY Mellon | $7.05M | 0.41 | 965,763 | -8.55% | -$659,467.32 | <0.01 | |
Citigroup | $6.89M | 0.4 | 943,493 | +69.82% | +$2.83M | 0.01 | |
UBS | $6.46M | 0.38 | 884,503 | +47.75% | +$2.09M | <0.01 | |
Schonfeld Group | $5.58M | 0.33 | 764,024 | New | +$5.58M | 0.04 | |
Standard Life | $5.12M | 0.3 | 700,865 | -15.93% | -$969,067.80 | 0.01 | |
Pekin Singer Strauss Asset Management Il | $3.96M | 0.23 | 542,660 | -29.65% | -$1.67M | 0.37 | |
Russell Investments Group Ltd | $3.91M | 0.23 | 536,297 | +100.67% | +$1.96M | 0.01 | |
Td Asset Management Inc | $3.73M | 0.22 | 510,336 | +75.41% | +$1.6M | <0.01 | |
Swiss National Bank | $3.35M | 0.2 | 458,300 | +6.73% | +$210,970.00 | <0.01 | |
Barclays | $3.35M | 0.2 | 459,268 | -78.99% | -$12.6M | <0.01 | |
Citadel Advisors LLC | $3.29M | 0.19 | 450,705 | +171.01% | +$2.08M | <0.01 | |
Two Sigma Advisers LP | $3.17M | 0.19 | 433,600 | New | +$3.17M | 0.01 | |
Seven Eight Capital Lp | $2.73M | 0.16 | 374,151 | +2,230.87% | +$2.61M | 0.29 | |
The Manufacturers Life Insurance Company | $2.64M | 0.16 | 361,774 | +51.76% | +$900,681.23 | <0.01 | |
Trexquant Investment LP | $2.58M | 0.15 | 353,709 | New | +$2.58M | 0.04 | |
Simplify Asset Management Inc | $2.56M | 0.15 | 350,000 | 0% | +$0 | 0.25 | |
RhumbLine Advisers | $2.46M | 0.14 | 337,574 | +3.31% | +$78,912.71 | <0.01 | |
Ubs Asset Management Americas Inc | $2.26M | 0.13 | 309,097 | -0.5% | -$11,307.70 | <0.01 | |
New York State Common Retirement Fund | $2.07M | 0.12 | 283,712 | +0.02% | +$467.18 | <0.01 | |
Natixis | $2.01M | 0.12 | 275,968 | New | +$2.01M | 0.01 | |
Voya Investment Management LLC | $2.01M | 0.12 | 275,690 | -45.5% | -$1.68M | <0.01 | |
Credit Suisse | $1.98M | 0.12 | 271,263 | +1.85% | +$35,967.10 | <0.01 | |
Marshall Wace | $1.97M | 0.12 | 270,466 | New | +$1.97M | <0.01 | |
J. Goldman & Company | $1.96M | 0.12 | 268,854 | -83.19% | -$9.71M | 0.09 |